- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Intensity Therapeutics Inc (INTS)
Track today's live Intensity Therapeutics (INTS) share price, performance and key data on this page with our current NASDAQ:INTS stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Intensity Therapeutics share price on the NASDAQ exchange. Use the dropdown to switch exchange for the INTS share price, head to our technical summary section, which provides analysis on Intensity Therapeutics share price buy/sell indicators using real-time data (or discuss the Intensity Therapeutics (INTS) stock price today with other investors in the Intensity Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:INTS share price (ISIN: US45828J2024) to enhance your trading decisions with our free investment tools and resources.
What Is the Intensity Therapeutics Inc Share Price Today?
The Intensity Therapeutics share price today is 4.390.
What Is the Stock Symbol for Intensity Therapeutics Inc
The stock symbol (or 'ticker') for Intensity Therapeutics Inc is "INTS."
What Stock Exchange Does Intensity Therapeutics Inc Trade On?
Intensity Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Intensity Therapeutics Inc a Good Stock to Buy?
Determining whether Intensity Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:INTS share price (ISIN: US45828J2024) to enhance your trading decisions with our free investment tools and resources.
What Is the Intensity Therapeutics Inc Share Price Today?
The Intensity Therapeutics share price today is 4.390.
What Is the Stock Symbol for Intensity Therapeutics Inc
The stock symbol (or 'ticker') for Intensity Therapeutics Inc is "INTS."
What Stock Exchange Does Intensity Therapeutics Inc Trade On?
Intensity Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Intensity Therapeutics Inc a Good Stock to Buy?
Determining whether Intensity Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
4.390
+0.380(+9.48%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.010
4.550
52 wk Range
0.407
43.500
Earnings results expected in 6 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.0104.550
52 wk Range
0.40743.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
INTS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
24.800
Upside
+464.92%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
Form 8K Intensity Therapeutics Inc For: 16 June- Investing.com
Form 4 Intensity Therapeutics Inc For: 1 July- Investing.com
- Form 4 Intensity Therapeutics Inc For: 1 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 24.800
(+464.92% Upside)
Earnings
Latest Release
07/05/2026
EPS / Forecast
-0.96 / -0.06
Revenue / Forecast
-- / --
Compare INTS to Peers and Sector
Metrics to compare | INTS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINTSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.0x | −1.4x | −0.3x | |
PEG Ratio | −0.01 | −0.03 | 0.00 | |
Price/Book | 1.1x | 2.7x | 2.6x | |
Price / LTM Sales | - | 60.5x | 3.0x | |
Upside (Analyst Target) | - | 81.8% | 56.6% | |
Fair Value Upside | Unlock | 2.1% | 10.2% | Unlock |
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Intensity Therapeutics (NASDAQ: INTS) Share Price Today?
The Intensity Therapeutics stock price today is 4.390 USD.
What Stock Exchange Does Intensity Therapeutics (INTS) Trade On?
Intensity Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Intensity Therapeutics?
The stock symbol (also called a 'ticker') for Intensity Therapeutics is "INTS."
What Is the Current Intensity Therapeutics Market Capitalisation?
As of today, Intensity Therapeutics (NASDAQ: INTS) market cap is 10.950M USD.
What Is Intensity Therapeutics's (INTS) Earnings Per Share (TTM)?
The Intensity Therapeutics EPS is currently -5.817 (Trailing Twelve Months).
When Is the Next Intensity Therapeutics Earnings Date?
Intensity Therapeutics's next earnings report will be released on 06/08/2026.
Is INTS a Buy or Sell From a Technical Analyst Perspective?
Based on today's Intensity Therapeutics moving averages and other technical indicators, the daily buy/sell signal for INTS stock is Strong Sell.
How Many Times Has Intensity Therapeutics Stock Split?
Intensity Therapeutics has split 2 times. (See the INTS stock split history page for full effective split date and price information.)
How Many Employees Does Intensity Therapeutics Have?
Intensity Therapeutics has 6 employees, based on their latest Companies House report.
What is the current trading status of Intensity Therapeutics (NASDAQ: INTS)?
As of 31/07/2026, Intensity Therapeutics (INTS) is trading at a share price of 4.390 USD, with a previous close of 4.050 USD. The stock has fluctuated within a day range of 4.010 USD to 4.550 USD, while its 52-week range spans from 0.407 USD to 43.500 USD.
What Is Intensity Therapeutics (INTS) Price Target According to Analysts?
The average 12-month price target for Intensity Therapeutics is 24.800 USD, with a high estimate of 32 USD and a low estimate of 12 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +464.92% Upside potential.
What Is the INTS Premarket Price?
INTS's last pre-market stock price is 4.170 USD. The pre-market share volume is 210.000, and the stock has decreased by 0.120, or 2.960%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.